NEJM trial halted: azithromycin fails for preschool wheeze

A large, well-designed trial has confirmed what many clinicians suspected, and it was stopped early because the answer was clear enough that continuing was pointless.

A randomised controlled trial of 840 preschool children aged 18 months to five years found azithromycin provided no clinical benefit over placebo for moderate-to-severe wheeze. The trial ran across eight emergency departments in the United States. It was halted at interim analysis. The drug did not help. And crucially: the negative result held even among the children who had pathogenic bacteria detected on nasopharyngeal testing.

This is the trial that answers the question GPs have been fielding from anxious parents for years.

---

What the trial found

The trial was published in the New England Journal of Medicine in 2026. Children with moderate-to-severe wheeze were randomised to five days of oral azithromycin or placebo. The primary outcome was cumulative caregiver-rated wheeze symptoms over five days using a validated scale.

At interim analysis, the independent safety committee found no clinical benefit in the azithromycin arm. The trial was halted. The finding was consistent across the overall cohort and in the pre-specified subgroup analysis of children with bacterial detection on nasopharyngeal swab.

This is worth sitting with for a moment. The clinical instinct — particularly when a child has bacteria detectable on swab and parents are asking whether there is something more to offer — has been to consider macrolide antibiotics. The reasoning is understandable: bacteria are present, inflammation is present, azithromycin has anti-inflammatory as well as antimicrobial properties. The trial says this instinct does not translate into clinical benefit.

---

Both sides of this

The trial is well-powered and was stopped early on the basis of a clear null result. It adds to an existing body of evidence that preschool wheeze — the majority of which is triggered by viral respiratory tract infection — does not respond to antibiotics. The organisms detected on nasopharyngeal testing in wheezing preschool children are often commensals or incidental findings rather than the causal agent of the wheezing episode.

At the same time, the trial has limits worth naming. It was conducted in US emergency departments, which means the enrolled children had moderate-to-severe wheeze severe enough to present for emergency care. The finding may or may not generalise to children managed in general practice with milder wheeze. The trial also does not address the specific clinical picture of a child with clear signs of bacterial infection — lobar pneumonia, significant purulent sputum, systemic signs of bacterial illness. Those children still warrant antibiotic consideration; they simply were not the population this trial enrolled.

What the trial does not support is the practice of empirical azithromycin in a wheezing preschool child with bacteria on a NP swab. That approach — using bacterial detection to justify prescribing — is now without evidence support.

The other dimension is antibiotic stewardship. Preschool wheeze is common. If azithromycin has been prescribed based on NP swab results, the volume of unnecessary antibiotic exposure in this age group is substantial. A clean trial answer gives GPs a stronger foundation for the conversation with parents who are expecting an antibiotic.

---

What this means in general practice this week

Update your approach to preschool wheeze. The acute management pathway — salbutamol for bronchodilation, systemic prednisolone for moderate-to-severe episodes — is unchanged. What this trial removes is the azithromycin step, including when bacteria are detectable on swab. If your practice has been using NP swab bacterial detection to guide antibiotic prescribing in wheezing preschool children, this is the evidence that changes that decision.

Have the conversation with parents about bacterial detection and causation. Families often arrive with a NP swab result from a hospital or urgent care visit showing bacteria. The instinct is understandable: bacteria are there, surely they need treating. The explanation that supports families without undermining their confidence is honest: detecting bacteria in the nose and throat of a young child — particularly during a respiratory illness — does not tell us those bacteria caused the wheeze, and treating them did not help in a trial of 840 children. The wheeze is being managed with the medicines that work.

Azithromycin is not an anti-inflammatory treatment for wheeze. The drug’s anti-inflammatory properties have generated clinical interest and some positive signal in adult asthma populations. This trial, in preschool wheeze specifically, found no benefit. The two populations are different and should not be conflated.

Document your reasoning when antibiotics are not prescribed. Families who have received antibiotics for wheeze in the past may push back. A clear, documented clinical rationale — “acute viral-triggered wheeze; antibiotics not clinically indicated per current evidence” — supports both good care and the conversation with parents.

The trial result is clear. The answer to “should we add azithromycin to manage preschool wheeze?” is now supported by the best-quality evidence available: no.

Verdict: yes — this changes how preschool wheeze with bacterial detection should be managed in general practice.

---

Sources cited

1. Trial finds no benefit for azithromycin in preschool wheeze — AusDoc, 17 September 2026